Latest Epidermal growth factor receptor Stories
MISSISSAUGA, ON, March 13 /PRNewswire-FirstCall/ - YM BioSciences Inc.
Singapore investigators to coordinate 700 patient trial of EGFR targeting antibody for treatment of head and neck cancer MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc.
Ensemble Discovery Corp today announced the extension of its collaboration with Roche to apply its proprietary diagnostic technology to personalized cancer therapy.
CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced new data from early non-clinical studies of Millennium/Takeda-discovered pipeline molecules highlighting novel therapeutic pathways in oncology.
Blockbuster cancer drug Avastin has suffered a setback, failing to improve overall survival when added to Tarceva in a Phase III trial for second-line advanced non-small cell lung cancer.
Chinese medical scientists say the drug gefitinib (Iressa) should be considered the first-line therapy for non-smoking Asian patients with lung cancer.
CALGARY, Sept. 2 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S.
The central role of receptor tyrosine kinases (RTKs) in cellular processes, especially in cancer, has made them an important target for several antibody- and small molecule-based inhibitors specific for various RTKs for the treatment of different tumour entities.
MISSISSAUGA, ON, Aug. 4 /PRNewswire-FirstCall/ -- YM BioSciences Inc.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.